AGN - AbbVie: A Strong Dividend Growth Pharmaceutical Company That Carries Risk
AbbVie (ABBV), a major pharmaceutical company focused primarily in the United States, has provided strong dividend growth since its inception. Not only is AbbVie’s dividend at an attractive starting yield of over 5.5%, but the company has also managed an impressive 20% five-year dividend growth rate. However, risks associated with the expiration of the patent for the company's key therapeutic Humira, its acquisition of Allergan (AGN) and its reliance of sales from the United States have brought concerns on whether this dividend growth is sustainable. However, in this article, I will